Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) — SEC Filings
Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) — 7 SEC filings. Latest: 6-K (Nov 26, 2025). Includes 3 6-K, 2 20-F/A, 2 20-F.
View Cordyceps Sunshine Biotech Holdings Co., Ltd. on SEC EDGAR
Overview
Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Nov 26, 2025: Cordyceps Sunshine Biotech Holdings Co., Ltd. filed a 6-K, which is a report for foreign private issuers, indicating they are providing information that is material to investors. This filing doesn't contain specific financial figures or events but rather serves as a general notification that the com
Sentiment Summary
Across 7 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 5 neutral. The dominant filing sentiment for Cordyceps Sunshine Biotech Holdings Co., Ltd. is neutral.
Filing Type Overview
Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) has filed 3 6-K, 2 20-F/A, 2 20-F with the SEC between Mar 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (7)
| Date | Form | Description | Risk |
|---|---|---|---|
| Nov 26, 2025 | 6-K | Cordyceps Sunshine Biotech Files 6-K, Fulfilling Reporting Duties | |
| Sep 23, 2025 | 20-F/A | RAJAF Amends 2023 Results, Highlights Single-Source & Funding Risks | high |
| Jun 13, 2025 | 20-F | Cordyceps Sunshine Biotech Soars: Revenue Up 45%, Net Income Jumps 81% | medium |
| Dec 6, 2024 | 6-K | Cordyceps Sunshine Biotech Dismisses Auditor TPS Thayer, LLC | medium |
| Oct 28, 2024 | 20-F/A | Cordyceps Sunshine Biotech Files 20-F/A Amendment | medium |
| Jul 5, 2024 | 20-F | Cordyceps Sunshine Biotech Files 2023 Annual Report | medium |
| Mar 19, 2024 | 6-K | Cordyceps Sunshine Biotech Dismisses Auditor | medium |
Risk Profile
Risk Assessment: Of RAJAF's 6 recent filings, 1 were flagged as high-risk, 5 as medium-risk, and 0 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- Szu Hao Huang
Industry Context
Cordyceps Sunshine Biotech Holdings Co., Ltd. operates in the biotechnology and medicinal mushroom sector, focusing on products derived from Cordyceps and Cattle camphor mushroom. This industry is characterized by a growing demand for natural health products and traditional Chinese medicine ingredients. However, it also faces challenges related to cultivation, quality control, and regulatory approvals for health claims.
Top Tags
regulatory-filing (2) · Biotech (2) · auditor-change (2) · annual-report (2) · biotech (2) · compliance (1) · foreign-issuer (1) · Taiwan (1) · China Risks (1) · Single Supplier Risk (1)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Ordinary Shares issued and outstanding | 111,120,000 | As of December 31, 2023 |
| Fiscal year end | 2023 | Period for which operational results were clarified and corrected |
| Amendment number | 2 | This is Amendment No. 2 to the Form 20-F |
| Number of major customers | 1 | For fiscal years ended December 31, 2023 and 2022, respectively |
| Number of major suppliers | 1 | For fiscal years ended December 31, 2023 and 2022, respectively |
| Revenue | $15.2M | Increased by 44.8% from $10.5 million in 2023 for fiscal year 2024 |
| Net Income | $3.8M | Increased by 81% from $2.1 million in 2023 for fiscal year 2024 |
| Revenue Growth | 44.8% | Year-over-year increase for fiscal year 2024 |
| Net Income Growth | 81% | Year-over-year increase for fiscal year 2024 |
| Ordinary Shares | 111,120,000 | Issued and outstanding as of December 31, 2024 |
| Fiscal Year End | 20241231 | Period covered by the annual report |
| SEC File Number | 333-269315 | Identifies the company's registration with the SEC |
| Fiscal Year End Date | 1231 | Specific date for the end of the fiscal year. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF)?
Cordyceps Sunshine Biotech Holdings Co., Ltd. has 7 recent SEC filings from Mar 2024 to Nov 2025, including 3 6-K, 2 20-F/A, 2 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of RAJAF filings?
Across 7 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 5 neutral. The dominant sentiment is neutral.
Where can I find Cordyceps Sunshine Biotech Holdings Co., Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cordyceps Sunshine Biotech Holdings Co., Ltd. (RAJAF) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cordyceps Sunshine Biotech Holdings Co., Ltd.?
Financial highlights for Cordyceps Sunshine Biotech Holdings Co., Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for RAJAF?
The investment thesis for RAJAF includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cordyceps Sunshine Biotech Holdings Co., Ltd.?
Key executives identified across Cordyceps Sunshine Biotech Holdings Co., Ltd.'s filings include Szu Hao Huang.
What are the main risk factors for Cordyceps Sunshine Biotech Holdings Co., Ltd. stock?
Of RAJAF's 6 assessed filings, 1 were flagged high-risk, 5 medium-risk, and 0 low-risk.
What are recent predictions and forward guidance from Cordyceps Sunshine Biotech Holdings Co., Ltd.?
Forward guidance and predictions for Cordyceps Sunshine Biotech Holdings Co., Ltd. are extracted from SEC filings as they are enriched.